InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences.

Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations.

Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.

Key Stats

• Today's Range: $0.97 to $1.00
• 50-Day Range: $0.81 to $1.20
• 52-Week Range: $0.68 to $1.77
• Volume: 19,223 shs
• Average Volume: 53,142 shs
• Market Capitalization: $54.13 million
• P/E Ratio: 33.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 27% of companies evaluated by MarketBeat, and ranked 750th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

InterCure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

InterCure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of InterCure is 33.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of InterCure is 33.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently decreased by 67.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.45

News Sentiment

InterCure has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for InterCure this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Institutions

8.34% of the stock of InterCure is held by institutions.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 7/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 350
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 33.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 1.48
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $78.47 million
• Price / Sales: 0.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.11 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 54,680,000
• Free Float: N/A
• Market Cap: $54.13 million
• Optionable: Optionable
• Beta: 1.39